Professional Association: Director of the Gene Therapy Program, Department of Pathology & Laboratory Medicine; Professor, Department of Internal Medicine at the University of Pennsylvania.
Education: Albion College, 1977. M.D and Ph.D., University of Michigan, 1984.
Following a residency in Internal Medicine at the Harvard affiliated Massachusetts General Hospital and a postdoctoral fellowship at MIT, he returned to the University of Michigan where he took his first faculty position beginning his studies in gene therapy.
Dr. James M. Wilson is the Professor and Director of the Gene Therapy Program in the Department of Pathology and Laboratory Medicine, and Professor in the Department of Internal Medicine at the University of Pennsylvania.
Nineteen years ago, he moved his laboratory and family to Philadelphia and joined the faculty of the University of Pennsylvania. His research interests are gene therapy, genetic diseases, virology and vaccines for infectious diseases. A primary focus of his research has been the study of cystic fibrosis and development of new treatments based on gene therapy. Dr. Wilson has published over 497 papers and chapters in books and is on the editorial board of 12 scientific journals, serving as Editor-in-Chief of Human Gene Therapy. He is the former president of the American Society of Gene Therapy and former trustee of Albion College and the Franklin Institute. Dr. Wilson is a scientific founder of REGENX BioSciences and is a consultant to REGENX Holdings, a founding member of REGENX BioSciences.